nadolol has been researched along with beta-thujaplicinol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Álvarez, M; Cheng, X; De Clercq, E; Gao, P; Liu, X; Luczkowiak, J; Menéndez-Arias, L; Pannecouque, C; Song, S; Sun, L; Zhan, P | 1 |
| Borrego, D; Clercq, E; Frutos-Beltrán, E; Gao, S; Kang, D; Liu, X; López-Carrobles, N; Menéndez-Arias, L; Pannecouque, C; Río, JMD; Wei, F; Xu, S; Zhan, P; Zhang, J; Zhang, L; Zhao, F | 1 |
2 other study(ies) available for nadolol and beta-thujaplicinol
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line; Cell Membrane Permeability; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; HIV Integrase; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Molecular Structure; Quinazolinones; Ribonuclease H, Human Immunodeficiency Virus; Structure-Activity Relationship | 2019 |
Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors.
Topics: Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors; Ribonuclease H; Ribonuclease H, Human Immunodeficiency Virus; Structure-Activity Relationship | 2022 |